近日,中国医学科学院肿瘤医院高亦博、刘骞团队在Molecular Cancer期刊发表的最新研究成果正与此相关:研究者们开发了可无创检测血液内游离DNA(cfDNA)甲基化特征的创新工具——ColonSecure,包含149个超甲基化特征,以用于对肠癌高危人群的“滴血验癌”,并在前瞻性研究中进行验证。 对近3500名肠癌高危人群开展的验证性研究结...
ColonSecure不仅能准确识别已发展到肠癌的患者,还能准确区分良性腺瘤与肠癌,以避免过度诊治:在1735例存在良性腺瘤的高危人群中,ColonSecure识别1556例为阴性,识别特异性达到89.7%。 参考文献: [1]Zhao F, Bai P, Xu J, et al. Efficacy of cell-free DNA methylation-based blood test for colorectal cancer scre...
[27]Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer[J]. BMC Med, 2011, 9: 133. DOI:10.1186/1741-7015-9-133 [28]Reinert T, Schøler LV, Thomsen R,...
4.US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(23):2564-2575. 5.https://www.genomeweb.com/business-news/cms-finalizes-blood-based-colon-cancer-screening-ncd-...
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells [J]. Cancer Res, 2001, 61(4):1659-1665. [14] Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6): 579...
Colon CancersProstate Cancer ScreeningsNeoplasiaMaynard, Mass.--Like the enigmatic Kilroy, who left his emblem everywhere he was stationed during World War II, cancer too leaves behind its mark. Indeed, molecular assay of blood and urine has made inroads in cervical and prostate cancer screening ...
For patients (pts) with colon cancer (CC), the detection of circulating tumor DNA (ctDNA) is associated with persistent disease after resection and outperforms traditional clinical and pathological features in prognosticating recurrence risk. We hypothesized that for pts with low-risk stage II CC,...
The new test was not superior on all counts though. Cologuard was less accurate than older blood tests at correctly ruling out cancer, reporting more growths when none were actually present. "It's a great new option I think," CBS News chief medical correspondentDr. Jon LaPook, a practicing...
Conclusions:A tumor informed ctDNA approach to AC selection is feasible for patients undergoing upfront resection of pancreatic adenocarcinoma, with the first blood draw to be scheduled at week 5, allowing time for ctDNA analysi...
A simple blood test would increase screening compliance, promoting early detection and better patient outcomes. The objective of this study is to demonstrate the performance of an improved sensitivity blood-based Septin 9 (SEPT9) methylated DNA test for colorectal cancer. Study variables include ...